Cargando…
Iloprost for the treatment of frostbite: a scoping review
We performed a scoping review to identify the extent of the literature describing the use of iloprost in the treatment of frostbite. Iloprost is a stable synthetic analog of prostaglandin I(2). As a potent inhibitor of platelet aggregation and vasodilator, it has been used to address the post-rewarm...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044161/ https://www.ncbi.nlm.nih.gov/pubmed/36966492 http://dx.doi.org/10.1080/22423982.2023.2189552 |
_version_ | 1784913306577797120 |
---|---|
author | Gauthier, Josianne Morris-Janzen, Dunavan Poole, Alexander |
author_facet | Gauthier, Josianne Morris-Janzen, Dunavan Poole, Alexander |
author_sort | Gauthier, Josianne |
collection | PubMed |
description | We performed a scoping review to identify the extent of the literature describing the use of iloprost in the treatment of frostbite. Iloprost is a stable synthetic analog of prostaglandin I(2). As a potent inhibitor of platelet aggregation and vasodilator, it has been used to address the post-rewarming reperfusion injury in frostbite. The search using iloprost and frostbite as key words and MeSH terms yielded 200 articles. We included in our review the literature examining iloprost for the treatment of frostbite in humans in the form of primary research, conference proceedings and abstracts. Twenty studies published from 1994 to 2022 were selected for analysis. The majority were retrospective case series consisting of a homogeneous population of mountain sport enthusiasts. A total of 254 patients and over 1000 frostbitten digits were included among the 20 studies. The larger case series demonstrated a decrease in amputation rates relative to untreated patients. Primary gaps in the literature include a paucity of randomised trials and relatively limited study populations to date. While the case evidence is promising, a multi-centre collaboration would be crucial to adequately power prospective randomised studies to definitively determine if iloprost has a role in the treatment of frostbite. |
format | Online Article Text |
id | pubmed-10044161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-100441612023-03-29 Iloprost for the treatment of frostbite: a scoping review Gauthier, Josianne Morris-Janzen, Dunavan Poole, Alexander Int J Circumpolar Health Arctic Military Conference in Cold Weather Medicine We performed a scoping review to identify the extent of the literature describing the use of iloprost in the treatment of frostbite. Iloprost is a stable synthetic analog of prostaglandin I(2). As a potent inhibitor of platelet aggregation and vasodilator, it has been used to address the post-rewarming reperfusion injury in frostbite. The search using iloprost and frostbite as key words and MeSH terms yielded 200 articles. We included in our review the literature examining iloprost for the treatment of frostbite in humans in the form of primary research, conference proceedings and abstracts. Twenty studies published from 1994 to 2022 were selected for analysis. The majority were retrospective case series consisting of a homogeneous population of mountain sport enthusiasts. A total of 254 patients and over 1000 frostbitten digits were included among the 20 studies. The larger case series demonstrated a decrease in amputation rates relative to untreated patients. Primary gaps in the literature include a paucity of randomised trials and relatively limited study populations to date. While the case evidence is promising, a multi-centre collaboration would be crucial to adequately power prospective randomised studies to definitively determine if iloprost has a role in the treatment of frostbite. Taylor & Francis 2023-03-26 /pmc/articles/PMC10044161/ /pubmed/36966492 http://dx.doi.org/10.1080/22423982.2023.2189552 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Arctic Military Conference in Cold Weather Medicine Gauthier, Josianne Morris-Janzen, Dunavan Poole, Alexander Iloprost for the treatment of frostbite: a scoping review |
title | Iloprost for the treatment of frostbite: a scoping review |
title_full | Iloprost for the treatment of frostbite: a scoping review |
title_fullStr | Iloprost for the treatment of frostbite: a scoping review |
title_full_unstemmed | Iloprost for the treatment of frostbite: a scoping review |
title_short | Iloprost for the treatment of frostbite: a scoping review |
title_sort | iloprost for the treatment of frostbite: a scoping review |
topic | Arctic Military Conference in Cold Weather Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044161/ https://www.ncbi.nlm.nih.gov/pubmed/36966492 http://dx.doi.org/10.1080/22423982.2023.2189552 |
work_keys_str_mv | AT gauthierjosianne iloprostforthetreatmentoffrostbiteascopingreview AT morrisjanzendunavan iloprostforthetreatmentoffrostbiteascopingreview AT poolealexander iloprostforthetreatmentoffrostbiteascopingreview |